Evidence map›Paper›PMID 38093301›Full record

ArticleStem cell research & therapy2023

New characterization and safety evaluation of human limbal stem cells used in clinical application: fidelity of mitotic process and mitotic spindle morphologies.

Marija Zekušić, Marina Bujić Mihica, Marija Skoko, Kruno Vukušić, Patrik Risteski, Jelena Martinčić, Iva M Tolić, Krešo Bendelja, Snježana Ramić, Tamara Dolenec and 8 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Marija ZekušićDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Marina Bujić MihicaDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia. marina.bujic@kbcsm.hr.
Marija SkokoDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Kruno VukušićDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia.
Patrik RisteskiDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia.
Jelena MartinčićDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia.
Iva M TolićDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia.
Krešo BendeljaCenter for Research and Knowledge Transfer in Biotechnology, Laboratory of Immunology, University of Zagreb, Zagreb, Croatia.
Snježana RamićDepartment of Oncological Pathology and Clinical Cytology 'Ljudevit Jurak', University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
Tamara DolenecDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Ivana Vrgoč ZimićDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Dominik PuljićDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Ivanka Petric VickovićClinical Department of Ophthalmology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Renata IvekovićClinical Department of Ophthalmology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Ivanka BatariloDepartment of Microbiology, Croatian Institute of Transfusion Medicine, Zagreb, Croatia.
Uršula Prosenc ZmrzljakMolecular Biology Department, BIA Separations CRO, Labena d.O.O, Ljubljana, Slovenia.
Alan HoffmeisterCharles River Laboratories, Canterbury, UK.
Tiha VučemiloDepartment of Transfusion and Regenerative Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
University Hospital Centre Zagreb · HRRudjer Boskovic Institute · HRBIA Separations (Slovenia) · SICharles River Laboratories (United Kingdom) · GBCroatian Institute of Transfusion Medicine · HRSisters of Charity Hospital · HRUniversity of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimbal stem cells (LSCs) are crucial for the regeneration of the corneal epithelium in patients with limbal stem cell deficiency (LSCD). Thus, LSCs during cultivation in vitro should be in highly homogeneous amounts, while potency and expression of stemness without tumorigenesis would be desirable. Therefore, further characterization and safety evaluation of engineered limbal grafts is required to provide safe and high-quality therapeutic applications.

methodsAfter in vitro expansion, LSCs undergo laboratory characterization in a single-cell suspension, cell culture, and in limbal grafts before transplantation. Using a clinically applicable protocol, the data collected on LSCs at passage 1 were summarized, including: identity (cell size, morphology); potency (yield, viability, population doubling time, colony-forming efficiency); expression of putative stem cell markers through flow cytometry, immunofluorescence, and immunohistochemistry. Then, mitotic chromosome stability and normal mitotic outcomes were explored by using live-cell imaging. Finally, impurities, bacterial endotoxins and sterility were determined.

resultsExpression of the stemness marker p63 in single-cell suspension and in cell culture showed high values by different methods. Limbal grafts showed p63-positive cells (78.7 ± 9.4%), Ki67 proliferation (41.7 ± 15.9%), while CK3 was negative. Impurity with 3T3 feeder cells and endotoxins was minimized. We presented mitotic spindles with a length of 11.40 ± 0.54 m and a spindle width of 8.05 ± 0.55 m as new characterization in LSC culture. Additionally, live-cell imaging of LSCs (n = 873) was performed, and only a small fraction < 2.5% of aberrant interphase cells was observed; 2.12 ± 2.10% of mitotic spindles exhibited a multipolar phenotype during metaphase, and 3.84 ± 3.77% of anaphase cells had a DNA signal present within the spindle midzone, indicating a chromosome bridge or lagging chromosome phenotype.

conclusionThis manuscript provides, for the first time, detailed characterization of the parameters of fidelity of the mitotic process and mitotic spindle morphologies of LSCs used in a direct clinical application. Our data show that p63-positive CK3-negative LSCs grown in vitro for clinical purposes undergo mitotic processes with extremely high fidelity, suggesting high karyotype stability. This finding confirms LSCs as a high-quality and safe therapy for eye regeneration in humans.

Indexed as

Epithelium, CornealLimbus CorneaeEndotoxinsHumansLimbal Stem CellsSpindle ApparatusStem CellsEndotoxinsAdvanced therapy medicinal productsLimbal graftLimbal stem cellLimbal stem cell deficiencyp63

Identifiers

PMID38093301
PMCPMC10720168
OpenAlexW4389669966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.